Celator Pharmaceuticals (CPXX) Presents Positive VYXEOS Phase 3 Data at ASCO; Strong OS Results Noted
Tweet Send to a Friend
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) announced results from its Phase 3 trial of VYXEOS (cytarabine: daunorubicin) Liposome for Injection (also ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
